{"doi":"10.1007/s00428-024-03764-1","title":"Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy","abstract":null,"journal":"Virchows Archiv","year":2024,"id":634382,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":668860,"name":"Yuka Takahashi","orcid":null,"position":1,"is_corresponding":false},{"id":640074,"name":"Hirokazu Taniguchi","orcid":"0000-0003-2414-8344","position":2,"is_corresponding":false},{"id":1645255,"name":"Tetsuro Ochi","orcid":null,"position":3,"is_corresponding":false},{"id":1645256,"name":"Haruhi Makino","orcid":null,"position":4,"is_corresponding":false},{"id":1645257,"name":"Shinichi Makita","orcid":null,"position":5,"is_corresponding":false},{"id":1645258,"name":"Noriko Iwaki","orcid":null,"position":6,"is_corresponding":false},{"id":1645259,"name":"Suguru Fukuhara","orcid":null,"position":7,"is_corresponding":false},{"id":1645260,"name":"Wataru Munakata","orcid":null,"position":8,"is_corresponding":false},{"id":1645261,"name":"Chitose Ogawa","orcid":null,"position":9,"is_corresponding":false},{"id":1121487,"name":"Koji Izutsu","orcid":"0000-0001-9129-8057","position":10,"is_corresponding":false},{"id":1645262,"name":"Akiko Miyagi Maeshima","orcid":"0000-0001-7251-7920","position":11,"is_corresponding":false},{"id":1645254,"name":"Yuto Kaimi","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy","abstract":"Brentuximab vedotin (BV), CD30 specific antibody drug conjugate, has been used to treat anaplastic large cell lymphoma (ALCL) and classic Hodgkin lymphoma (CHL); it is also used in the treatment of other CD30-positive peripheral T-cell lymphomas. We aimed to investigate the incidence and clinicopathological characteristics of patients with ALCL or CHL with loss of or decrease in CD30 expression after BV-containing therapy. Twelve and nine patients with refractory/relapsed CHL and ALCL, respectively, were analyzed after receiving BV-containing therapy. In four ALCL patients (44%), CD30 expression was lost/decreased in re-biopsy materials, including one with complete loss and three with a reduction of less than 20%. All 12 CHL patients showed consistent CD30 expression levels after BV treatment. Compared with five ALCL patients with consistent CD30 expression, four ALCL patients with a loss of/decrease in CD30 expression received a higher cumulative dose of BV (P = 0.014) and revealed a lower intensity of CD30 expression in initial biopsy materials (P = 0.017). The subtypes of ALCL (ALK positive, ALK negative, and primary cutaneous) were not related to the loss of/decrease in CD30 expression. In conclusion, 44% of ALCL patients, regardless of histological subtypes, showed a loss of/decrease in CD30 expression after receiving BV-containing therapy, but this phenomenon was not observed in CHL patients. A higher cumulative dose of BV and a lower amount of CD30 antigen in tumor cells in the initial biopsy materials might be predictors of a loss of/decrease in CD30 expression in ALCL patients.","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38349387","pmcid":null,"openalex_id":"https://openalex.org/W4391784748","authors":[],"funders":[{"funder_name":"Japan Agency for Medical Research and Development","grant_id":"23ck0106670h0003","title":null}],"total_grants":1,"fwci":2.7695,"citation_percentile":0.90123389,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":7},{"year":2026,"count":1}],"oa_status":"closed","license":"https://www.springernature.com/gp/researchers/text-and-data-mining","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/s00428-024-03764-1.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s00428-024-03764-1/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s00428-024-03764-1","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38349387","host_type":"repository"}],"fields_of_study":["Lymphoma Diagnosis and Treatment","Cutaneous lymphoproliferative disorders research","T-cell and Retrovirus Studies","Humans","Brentuximab Vedotin","Lymphoma, Large-Cell, Anaplastic","Immunoconjugates","Ki-1 Antigen","Hodgkin Disease","Receptor Protein-Tyrosine Kinases"],"mesh_terms":["Brentuximab Vedotin","Hodgkin Disease","Humans","Lymphoma, Large-Cell, Anaplastic","Ki-1 Antigen","Immunoconjugates","Receptor Protein-Tyrosine Kinases"],"keywords":["Brentuximab vedotin","CD30","Anaplastic large-cell lymphoma","Medicine","Biopsy","Lymphoma","Large cell","Internal medicine","Pathology","Cancer","Adenocarcinoma","Immunohistochemistry","Anaplastic Large Cell Lymphoma","Classic Hodgkin Lymphoma"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T13:34:31.414854Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}